SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

Brera Holdings is trending due to its announced rebrand to Solmate, a Solana-backed digital asset treasury, fueled by a recent $300 million private placement. The community is actively discussing the potential for a short squeeze given the low float, while also drawing comparisons to other crypto treasury stocks like $QMMM, anticipating a similar surge. Some traders express caution, citing potential dilution from warrants associated with the private placement.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as community members discuss its potential connection to Panasonic's recently announced solid-state battery development and the implications for Tesla, fueled by existing partnerships and shared board members. Investors are speculating on a potential partnership announcement given recent milestones, insider activity, and the broader shift towards solid-state battery technology. The community is closely watching for news that could drive the stock higher, with some drawing comparisons to past surges.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending amid discussions around the cancellation of Jimmy Kimmel's show, sparking debates about free speech and cancel culture from both conservative and liberal viewpoints. The community is divided, with some calling for boycotts and others defending Disney's decision, creating volatility in the stock. Broader concerns include the company's handling of streaming services and its response to political pressures.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending due to post-earnings volatility, with the community debating whether the initial positive reaction will hold. Discussions revolve around the company's guidance, potential impacts from tariffs, and cost-cutting measures. Community members are also weighing bullish and bearish scenarios for the stock's short-term trajectory.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Lennar Corp. is trending following its Q3 earnings report, which revealed that the company missed expectations amidst ongoing housing market pressures. Community discussions are focused on the lowered guidance and potential impact of interest rates and inflation on the housing market, while some suggest that this may be a buying opportunity. The news is impacting the broader homebuilder sector, with attention on how Lennar's results reflect the overall health of the housing market.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as it approaches all-time highs, fueled by bullish sentiment around potential interest rate cuts and possible inclusion in the S&P 500. The community is actively discussing the stock's breakout potential, while also weighing the possibility of profit-taking after a significant run-up. Optimistic investors are highlighting long-term growth prospects and management's strategic vision, while short-term traders eye potential volatility around upcoming announcements.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk ($TTD) is trending as investors grapple with its recent downturn, despite strong fundamentals, as the stock approaches multi-year lows. Community members are actively discussing whether the dip represents a buying opportunity or a value trap, with some citing concerns over competition and potential market manipulation. Others point to upcoming catalysts, such as the shareholder meeting and potential benefits from future rate cuts, sparking debates about the company's long-term prospects.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the impact of recently ended tariff exemptions and potential for a dividend cut, despite a high current yield. Some traders are noting technical indicators suggesting a possible bottom, while others point to insider buying as a positive sign. Overall, community sentiment appears mixed as traders assess whether the current price reflects underlying economic concerns or presents a value opportunity.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending after news of a significant partnership and investment from Nvidia, sparking optimism about Intel's role in AI and data centers. The community is buzzing about the potential for Intel to regain market share and reach new price levels, while some are cautious about potential pullbacks. Discussions include the strategic implications of the partnership, with some viewing it as a move to counter AMD's growing influence.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending due to a recently announced $1.4 billion partnership to build AI data centers, leading to a price target increase from Alliance Global Partners. The community is discussing the potential for a short squeeze and the company's undervaluation compared to its peers in the AI sector. Investors are also anticipating upcoming events, including the O.N.E. Amazon launch, for further catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIRA Pharmaceuticals Inc saw its shares rise to the highest levels in nearly two months after the clinical-stage pharmaceutical company announced the board’s approval of its planned acquisition of SKNY Pharmaceuticals Inc, a deal valued at over $60 million.The acquisition, which still requires approval from MIRA and SKNY’s shareholders, has been valued based on third-party analysis conducted by Moore Financial Consulting.&nbsp;SKNY Pharmaceuticals has an enterprise value of approximately $30.5 million, while MIRA's value stands at $30 million, bringing the combined enterprise value to over $60 million.Shares of MIRA Pharmaceuticals have gained 8.7% year-to-date, closing at $1.25 on Thursday, before dipping 6.4% in after-hours trading.MIRA CEO Erez Aminov emphasized that the merger combines two robust pipelines and a unified strategy, with a focus on developing therapies for obesity and nicotine dependence.&nbsp;Under the terms of the merger, SKNY is required to hold at least $5 million in cash or other assets to be transferred at closing.&nbsp;MIRA is preparing to file with the U.S. Securities and Exchange Commission to seek shareholder approval for the deal.SKNY Pharmaceuticals’ lead compound, SKNY-1, is being developed as a next-generation oral therapeutic targeting CB1 and CB2 cannabinoid receptors, as well as monoamine oxidase B (MAO-B), which plays a key role in dopamine metabolism and addiction regulation.&nbsp;The compound is being evaluated for its potential to address both metabolic dysfunction and nicotine dependence, with applications in two high-value therapeutic areas.MIRA’s leadership views the addition of SKNY-1 to its pipeline as a key step in positioning the company to capitalize on these growing markets. Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor, Itzchak Angel, said the pharmacological profile of SKNY-1 could make it an effective treatment for both addiction and metabolic disorders.&nbsp;Early data from the compound’s development has been promising, according to Angel.On Stocktwits, sentiment was described as 'bullish' amid a 1,350% surge in 24-hour message volume.&nbsp;One user noted that the merger would be a significant win, expressing confidence that shareholders from both companies would approve, while another shared frustration over a pre-market entry at $1.70, followed by an immediate pullback.<stembedurl>https://stocktwits.com/BearTamerTrading/message/613998754</stembedurl><stembedurl>https://stocktwits.com/Kc24mo/message/613981879</stembedurl>The stock has risen 8.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong

Retail sentiment on Stocktwits surged, with users expressing optimism about the merger’s success, despite a pullback in after-hours trading.

Equity

Shares of Mira Pharmaceuticals&nbsp;gained over 19% on Wednesday, marking their best session in over a month, after the company's oral ketamine analog showed promising data in a preclinical study.Mira said its Ketamir-2 therapy significantly reduced pain symptoms in rats, with some test animals returning to pre-diabetic sensitivity levels.The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects, the company added.On Stocktwits, the news sent 24-hour message volume involving Mira soaring 8,500% by late Wednesday — the highest among all healthcare stocks — with sentiment turning even more 'extremely bullish.'<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/MIRA_sentiment_and_message_volume_as_of_April_16_png_9320cb3838.webp" alt="MIRA sentiment and message volume as of April 16.png" width="1318" height="316"><figcaption>MIRA sentiment and message volume as of April 16. | source: Stocktwits</figcaption></figure>One watcher expects the stock to cross the $1.2 mark on Thursday easily.<stembedurl>https://stocktwits.com/BadBritt/message/611883890</stembedurl>Another said a new 52-week high was imminent.<stembedurl>https://stocktwits.com/HMIC/message/611835137</stembedurl>Mira has already begun dosing and testing Ketamir-2 in a Phase I trial in Israel, which is expected to be completed in the fourth quarter of 2025.&nbsp;A Phase IIa trial in diabetic neuropathy is set to begin by the end of 2025, with efficacy data anticipated in early 2026.&nbsp;Mira is also developing a topical formulation for localized pain and exploring Ketamir-2's potential in PTSD treatment.Separately, Mira is progressing with its acquisition of SKNY Pharmaceuticals and sees promise in SKNY-1, a next-generation oral therapy targeting obesity and smoking cessation.Mira Pharmaceuticals' stock has lost over 8% this year but has risen nearly 29% over the past 12 months.Shares of the company fell over 11% after-hours on Wednesday, likely due to profit-taking.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial

The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects. 

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data

MIRA Pharmaceuticals stock surged on Thursday following new preclinical data on Ketamir-2, MIRA's novel oral ketamine analog, highlighting its unique selectivity and favorable safety profile for...

Small-cap biotech Mira Pharmaceuticals (MIRA) has experienced a meteoric rise and subsequent plunge, captivating retail investors in the process.The company's stock surged a staggering 627% on Monday following promising preclinical data for its novel oral ketamine analog, Ketamir-2. This dramatic increase sparked a frenzy of interest, with the number of Stocktwits followers surging over 212% in just one week.Ketamir-2 has shown potential as a treatment for neurological and neuropsychiatric disorders, according to media <a href="https://www.benzinga.com/news/24/07/39885749/nano-cap-mira-pharmaceuticals-oral-ketamine-analog-shows-potential-in-neuropsychiatric-disorders?utm_source=TechInvestorNews&amp;utm_campaign=partner_feed&amp;utm_medium=partner_feed&amp;utm_content=site">reports</a>. Unlike traditional ketamine, it exhibits better oral bioavailability and appears to have a reduced risk of side effects. These advantages could position Mira as a significant player in the development of novel therapies.The company is also preparing to submit an Investigational New Drug (IND) application to the FDA by the end of this year.However, the euphoria was short-lived. The stock plummeted over 54% on Tuesday, prompting some to take profits while they still had them.Although some investors believe this represents a buying opportunity, others remain cautious, citing the long road to commercialization and the potential for future volatility.The Stocktwits stream had plenty of bearish posts, like the one from “<a href="https://stocktwits.com/Wolf_Of_Penny_Stocks/message/580409064">Wolf_of_penny_stocks</a>”, advising investors to “scalp and run” as Monday’s stock move was a “pump on preclinical data… even if they are successful it will take another 8-10 years before they generate any revenue.”<figure class="image"><img style="aspect-ratio:1320/450;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Stocktwits_user_comment_on_MIRA_stream_Jul_23_1a46479621.png" alt="Stocktwits user comment on MIRA stream Jul 23.png" width="1320" height="450"><figcaption>Stocktwits user comment on MIRA stream Jul 23</figcaption></figure>The rapid rise and fall of Mira Pharmaceuticals highlights the speculative nature of the biotech sector. While preclinical data is undoubtedly encouraging, investors must approach such volatile stocks with caution and conduct thorough due diligence before making investment decisions, as many posts on MIRA’s Stocktwits stream suggest. &nbsp;

Why Small-Cap Mira Pharma's Retail Following Has Tripled From Last Week

The tiny company's Mira Pharma stock price and Stocktwits following exploded after promising preclinical data for its novel drug, Ketamir-2.

Mira Pharma's Retail Following Has Tripled From Last Week

The tiny company's stock price and Stocktwits following exploded after promising preclinical data for its novel drug, Ketamir-2. However, a subsequent freefall has left investors wondering if this was a flash in the pan or the start of something bigger.

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders

MIRA Pharmaceuticals reveals preclinical data for its novel oral ketamine analog, Ketamir-2, targeting neurological and neuropsychiatric disorders. With superior oral absorption and efficacy...

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety...

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year Mira Pharmaceuticals Announces...

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel...

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Mira Pharmaceuticals Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$1.27
Prev Close	$1.29
Open	$1.28
Dividend Yield	0.00%
50-Day Moving Average	$1.50
Beta	0.00
Avg. Volume	208,251.90
PE Ratio	-2.69

52-Week High	$2.56
52-Week Low	$0.73
Market Capitalization	$24.6M
EPS (Annual)	-$0.5085
Price to Book	39.35
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MIRA
Mira Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MIRA News

MIRA Mira Pharmaceuticals Inc